ClinicalTrials.gg
CompletedNCT00565084Updated Apr 10, 2015Results posted

Tolerability and Efficacy of Ibuprofen 800 mg in a Walking Model of Osteoarthritis Pain (0000-057)

A Phase 1 interventional study of ibuprofen and Placebo in Osteoarthritis, Knee, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2015-04-10.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Study summary

The purpose of the study is to see if generic ibuprofen has an effect on osteoarthritis knee pain during a series of timed walks on a treadmill.

02

Conditions studied

  • Osteoarthritis, Knee
03

In context

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

This study's enrollment of 33 is below the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.

Browse Osteoarthritis, Knee studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The primary source of pain is the study knee of one lower extremity
  • Patient is willing to limit alcohol and caffeine intake
  • Aside from osteoarthritis, patient is in generally good health
  • Patient is capable of completing protocol specified walks
  • Patient is able to understand and complete questionnaires in English
  • Patient has previously benefited from the use of either NSAIDs, COX-2 inhibitors, or acetaminophen

Exclusion criteria

Exclusion Criteria:

  • Patient has another condition which could interfere with evaluating pain in the knee being tested
  • Patient is not able to take a non-steroidal anti-inflammatory drug (NSAID) such as ibuprofen
  • Patient has a history or current evidence of stroke, , liver disease or cancer
  • Patient has a history or current evidence of dizziness, unsteadiness, or falling
  • Patient has congestive heart failure, unstable angina or uncontrolled high blood pressure
  • Patient has a history of stomach, digestive track, or small intestine surgery
  • Patient is unable to complete the study questionnaires in English
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
33 participants (actual)

Study arms

  • Active comparator
    1

    Ibuprofen

    Drug: ibuprofen

  • Placebo comparator
    2

    Placebo 1

    Drug: Placebo

  • Placebo comparator
    3

    Placebo 2

    Drug: Placebo

Interventions

  • Patients will receive 800 mg ibuprofen in one of the three treatment periods.

  • DrugPlacebo

    Patients will receive placebo to ibuprofen in two of the three treatment periods.

06

What researchers measure

Primary outcomes

  1. Change in Average Pain Intensities Measured From the Pre-Treatment Walk (Baseline) at 3 Post-Treatment Walks

    Pain intensities(PIs) were measured at pre-dose and 3 post-dose walks (15 Minutes Each Separated by a 45-Minute Rest Interval) on an 11 point scale(0=no pain; 10=worst pain) and averaged for each walk. Change from baseline was average of post-dose PIs minus average of pre-dose PI.

    Time frame: All pain intensities measured from the pre-treatment walk and 3 post-treatment walks (within 3 and half hours post dose, 15 minutes each walk separated by a 45-minute rest interval)

07

Results

Posted Jul 7, 2009

Participant flow

First Patient Entered 16 Mar 2007 Multicenter, 3 sites

First Treatment Period
Participant flow — First Treatment Period
MilestonePlacebo-Placebo-IbuprofenPlacebo-Ibuprofen-PlaceboIbuprofen-Placebo-Placebo
Started111111
Completed111111
Not completed000
Second Treatment Period
Participant flow — Second Treatment Period
MilestonePlacebo-Placebo-IbuprofenPlacebo-Ibuprofen-PlaceboIbuprofen-Placebo-Placebo
Started111111
Completed111111
Not completed000
Third Treatment Period
Participant flow — Third Treatment Period
MilestonePlacebo-Placebo-IbuprofenPlacebo-Ibuprofen-PlaceboIbuprofen-Placebo-Placebo
Started111111
Completed111111
Not completed000

Outcome measures

PrimaryChange in Average Pain Intensities Measured From the Pre-Treatment Walk (Baseline) at 3 Post-Treatment Walks

Pain intensities(PIs) were measured at pre-dose and 3 post-dose walks (15 Minutes Each Separated by a 45-Minute Rest Interval) on an 11 point scale(0=no pain; 10=worst pain) and averaged for each walk. Change from baseline was average of post-dose PIs minus average of pre-dose PI.

Time frame:
All pain intensities measured from the pre-treatment walk and 3 post-treatment walks (within 3 and half hours post dose, 15 minutes each walk separated by a 45-minute rest interval)
Reported as:
Least squares mean · Units on a Scale
Change in Average Pain Intensities Measured From the Pre-Treatment Walk (Baseline) at 3 Post-Treatment Walks
Units on a ScaleIbuprofenPlacebo 1Placebo 2
Change in Average Pain Intensities Measured From the Pre-Treatment Walk (Baseline) at 3 Post-Treatment Walks0.24 ± 0.770.18 ± 0.770.18 ± 0.77
Statistical analysis
  • Ibuprofen vs Placebo 1 vs Placebo 2 · ANOVA · p = 0.743 · Difference in ls means: 0.06 · 90% CI -0.23 to 0.35

Adverse events

Collected over From consent to 14 day follow up after all treatment periods was from 16-Mar-2007 to 10-Dec-2007. First study dosing to last dosing period was from 23-Mar-2007 to 03-Dec-2007.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo-Placebo-Ibuprofen—0/11 (0%)3/11 (27.3%)
Placebo-Ibuprofen-Placebo—0/11 (0%)3/11 (27.3%)
Ibuprofen-Placebo-Placebo—1/11 (9.1%)3/11 (27.3%)
Most frequent serious events
Most frequent serious events
EventPlacebo-Placebo-IbuprofenPlacebo-Ibuprofen-PlaceboIbuprofen-Placebo-Placebo
Breast Ductal Cancer InfiltratingNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/110/111/11
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlacebo-Placebo-IbuprofenPlacebo-Ibuprofen-PlaceboIbuprofen-Placebo-Placebo
DiarrheaGastrointestinal disorders0/111/110/11
Boil on ButtockInfections and infestations0/110/111/11
Cold SymptomsInfections and infestations1/110/110/11
Urinary Track InfectionInfections and infestations1/110/110/11
Groin PainMusculoskeletal and connective tissue disorders0/111/110/11
Hip DiscomfortMusculoskeletal and connective tissue disorders0/111/110/11
Pain in Joint involving handMusculoskeletal and connective tissue disorders0/111/110/11
Pain in HipMusculoskeletal and connective tissue disorders0/110/111/11
Tibia PainMusculoskeletal and connective tissue disorders0/111/110/11
Unilateral Leg PainMusculoskeletal and connective tissue disorders0/110/111/11

Baseline characteristics

Age, Continuous
Age, Continuous(years)Overall Study
Mean60.78 (47 to 80)
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female8
Male25
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Peeva E, Beals CR, Bolognese JA, Kivitz AJ, Taber L, Harman A, Smugar SS, Moskowitz RW. A walking model to assess the onset of analgesia in osteoarthritis knee pain. Osteoarthritis Cartilage. 2010 May;18(5):646-53. doi: 10.1016/j.joca.2009.12.008. Epub 2010 Feb 6. PubMed 20175977 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2007
First posted
Nov 29, 2007
Start
Mar 2007
Primary completionActual
Dec 2007
CompletionActual
Dec 2007
Results first posted
Jul 7, 2009
Last update
Apr 10, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00565084
Responsible party
Sponsor
First posted
Nov 29, 2007
Start date
Mar 2007
Primary completion
Dec 2007
Completion
Dec 2007
Results posted
Jul 7, 2009
Last update
Apr 10, 2015

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion